Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesCapital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pediatrix Medical (MD) Cash from Operations: 2009-2024

Historic Cash from Operations for Pediatrix Medical (MD) over the last 16 years, with FY2024 value amounting to $217.2 million.

  • Pediatrix Medical's Cash from Operations rose 3712.77% to $138.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $42.7 million, marking a year-over-year increase of 19974.52%. This contributed to the annual value of $217.2 million for FY2024, which is 4871.89% up from last year.
  • As of FY2024, Pediatrix Medical's Cash from Operations stood at $217.2 million, which was up 4871.89% from $146.1 million recorded in FY2023.
  • Over the past 5 years, Pediatrix Medical's Cash from Operations peaked at $217.2 million during FY2024, and registered a low of $113.8 million during FY2021.
  • In the last 5 years, Pediatrix Medical's Cash from Operations had a median value of $182.3 million in 2022 and averaged $172.8 million.
  • As far as peak fluctuations go, Pediatrix Medical's Cash from Operations tumbled by 4440.43% in 2021, and later skyrocketed by 6026.02% in 2022.
  • Pediatrix Medical's Cash from Operations (Annual) stood at $204.6 million in 2020, then crashed by 44.4% to $113.8 million in 2021, then skyrocketed by 60.26% to $182.3 million in 2022, then fell by 19.87% to $146.1 million in 2023, then skyrocketed by 48.72% to $217.2 million in 2024.
  • Its Cash from Operations stands at $217.2 million for FY2024, versus $146.1 million for FY2023 and $182.3 million for FY2022.